NEW YORK (GenomeWeb) – Human Longevity today announced an agreement to license, develop, and co-promote Celgene Cellular Therapeutics' placental cell population, PSC-100.

As part of the deal, CCT, a Celgene company, has made an equity investment of an undisclosed amount into La Jolla, Calif.-based Human Longevity. Other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.